Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

There are no other options in the adjuvant setting. If people develop distant metastases after surgical resection, treatment options include chemotherapy or a tyrosine kinase inhibitor. The committee ...

Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows ...

A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...

Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib. A case report of a ...

The Scottish Medicines Consortium (SMC) has approved Tagrisso (osimertinib) for use within NHS Scotland as a monotherapy for adjuvant treatment after tumour removal in adult patients with stage IB ...

“We know patients benefited from osimertinib in the ADAURA trial ... approach for patients with EGFR mutations in the adjuvant setting [after the primary treatment has completed], and now ...